Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer (Q24244156)

1

0 references

Mike Shelley

2

0 references

Craig Harrison

3

0 references

Bernadette Coles

4

0 references

Malcolm Mason

Cochrane Database of Systematic Reviews

6

0 references

publication date

18 October 2006

0 references

published in

0 references

cites work

Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006019.PUB2

Report of a multicenter Canadian phase III randomized trial of 3 months vs. 8 months neoadjuvant androgen deprivation before standard-dose radiotherapy for clinically localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006019.PUB2

Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006019.PUB2

Long-term followup of a randomized trial of 0 versus 3 months of neoadjuvant androgen ablation before radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006019.PUB2

Acceptability of short term neo-adjuvant androgen deprivation in patients with locally advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006019.PUB2

Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006019.PUB2

Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006019.PUB2

Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma--long-term results of phase III RTOG 85-31.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006019.PUB2

Neoadjuvant hormone treatment with leuprolide acetate depot 3.75 mg and cyproterone acetate, before radical prostatectomy: a randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006019.PUB2

Effects of complete androgen blockade for 12 and 24 weeks on the pathological stage and resection margin status of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006019.PUB2

Bicalutamide ('Casodex') 150 mg as adjuvant to radiotherapy in patients with localised or locally advanced prostate cancer: results from the randomised Early Prostate Cancer Programme

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006019.PUB2

Prolonged neoadjuvant combined androgen blockade leads to a further reduction of prostatic tumor volume: three versus six months of endocrine therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006019.PUB2

Prospective randomized trial comparing flutamide as adjuvant treatment versus observation after radical prostatectomy for locally advanced, lymph node-negative prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006019.PUB2

Long-term results of a randomized trial for the treatment of Stages B2 and C prostate cancer: radical prostatectomy versus external beam radiation therapy with a common endocrine therapy in both modalities.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006019.PUB2

A prospective and randomized study of primary hormonal therapy for patients with localized or locally advanced prostate cancer unsuitable for radical prostatectomy: results of the 5-year follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006019.PUB2

Superior anti-tumor efficacy of bicalutamide 80 mg in combination with a luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist monotherapy as first-line treatment for advanced prostate cancer: interim results of a randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006019.PUB2

Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer: results of a randomized, double-blind, placebo-controlled clinical trial. PLESS Study Group. Proscar Long-term Efficacy and Safety Stud

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006019.PUB2

Pathologic effects of neoadjuvant cyproterone acetate on nonneoplastic prostate, prostatic intraepithelial neoplasia, and adenocarcinoma: a detailed analysis of radical prostatectomy specimens from a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006019.PUB2

6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006019.PUB2

Long-term outcome by risk factors using conformal high-dose-rate brachytherapy (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006019.PUB2

Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006019.PUB2

Endocrine therapy with or without radical prostatectomy for T1b-T3N0M0 prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006019.PUB2

Subset analysis of RTOG 85-31 and 86-10 indicates an advantage for long-term vs. short-term adjuvant hormones for patients with locally advanced nonmetastatic prostate cancer treated with radiation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006019.PUB2

A randomised comparison of bicalutamide ('Casodex') 150 mg versus placebo as immediate therapy either alone or as adjuvant to standard care for early non-metastatic prostate cancer. First report from the Scandinavian Prostatic Cancer Group Study No.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006019.PUB2

Bicalutamide (150 mg) versus placebo as immediate therapy alone or as adjuvant to therapy with curative intent for early nonmetastatic prostate cancer: 5.3-year median followup from the Scandinavian Prostate Cancer Group Study Number 6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006019.PUB2

Is the efficacy of hormonal therapy affected by lymph node status? data from the bicalutamide (Casodex) Early Prostate Cancer program

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006019.PUB2

Hormone therapy adjuvant to external beam radiotherapy for locally advanced prostate carcinoma: a complication-adjusted number-needed-to-treat analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006019.PUB2

Combination therapy for prostate cancer. Endocrine and biologic basis of its choice as new standard first-line therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006019.PUB2

Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006019.PUB2

Androgen suppression plus radiation versus radiation alone for patients with stage D1/pathologic node-positive adenocarcinoma of the prostate: updated results based on national prospective randomized trial Radiation Therapy Oncology Group 85-31.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006019.PUB2

Role of hormonal therapy in the management of intermediate- to high-risk prostate cancer treated with permanent radioactive seed implantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006019.PUB2

Incidence and clinical significance of false-negative sextant prostate biopsies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006019.PUB2

Adjuvant therapy for localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006019.PUB2

Evaluation of adjuvant estramustine phosphate, cyclophosphamide, and observation only for node-positive patients following radical prostatectomy and definitive irradiation. Investigators of the National Prostate Cancer Project

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006019.PUB2

Bicalutamide as Immediate Therapy Either Alone or as Adjuvant to Standard Care of Patients with Localized or Locally Advanced Prostate Cancer: First Analysis of the Early Prostate Cancer Program

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006019.PUB2

Immediate treatment with bicalutamide 150mg as adjuvant therapy significantly reduces the risk of PSA progression in early prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006019.PUB2

Effect of a short course of neoadjuvant hormonal therapy on the response to subsequent androgen suppression in prostate cancer patients with relapse after radiotherapy: a secondary analysis of the randomized protocol RTOG 86-10.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006019.PUB2

Effect of neoadjuvant endocrine therapy (combined androgen blockade) on normal prostate and prostatic carcinoma. A randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006019.PUB2

Neoadjuvant hormone therapy and radical prostatectomy: the jury is still out.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006019.PUB2

Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer program at median followup of 5.4 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006019.PUB2

Effectiveness of adjuvant intermittent endocrine therapy following neoadjuvant endocrine therapy and external beam radiation therapy in men with locally advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006019.PUB2

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006019.PUB2

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006019.PUB2

Long-term hormone therapy and radiation is cost-effective for patients with locally advanced prostate carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006019.PUB2

A cost-outcome analysis of long-term adjuvant goserelin in addition to radiotherapy for locally advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006019.PUB2

Economic analysis of a phase III clinical trial evaluating the addition of total androgen suppression to radiation versus radiation alone for locally advanced prostate cancer (Radiation Therapy Oncology Group protocol 86-10)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006019.PUB2

Development of anemia and recovery in prostate cancer patients treated with combined androgen blockade and radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006019.PUB2

7 January 2021

Regressive changes and neuroendocrine differentiation in prostate cancer after neoadjuvant hormonal treatment

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006019.PUB2

7 January 2021

Short term neoadjuvant androgen deprivation therapy does not affect prostate specific membrane antigen expression in prostate tissues

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006019.PUB2

7 January 2021

Adjuvant estrogen following radiation therapy for stage C adenocarcinoma of the prostate: long-term results of a prospective randomized study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006019.PUB2

7 January 2021

Hormonal cytoreduction in locally advanced carcinoma of the prostate treated with definitive radiotherapy: preliminary results of RTOG 83-07

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006019.PUB2

7 January 2021

Phase II trial of hormonal cytoreduction with megestrol and diethylstilbestrol in conjunction with radiotherapy for carcinoma of the prostate: outcome results of RTOG 83-07

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006019.PUB2

7 January 2021

Combined orchiectomy and external radiotherapy versus radiotherapy alone for nonmetastatic prostate cancer with or without pelvic lymph node involvement: a prospective randomized study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006019.PUB2

7 January 2021

Predictors of pathological stage before neoadjuvant androgen withdrawal therapy and radical prostatectomy. The Canadian Urologic Oncology Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006019.PUB2

7 January 2021

Randomized, prospective, controlled study comparing radical prostatectomy alone and neoadjuvant androgen withdrawal in the treatment of localized prostate cancer. Canadian Urologic Oncology Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006019.PUB2

7 January 2021

Randomized study of neoadjuvant testicular androgen ablation therapy before radical prostatectomy in men with clinically localized prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006019.PUB2

7 January 2021

Neuroendocrine differentiation is not prognostic of failure after radical prostatectomy but correlates with tumor volume

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006019.PUB2

7 January 2021

Effect of complete androgen blockade on pathologic stage and resection margin status of prostate cancer: progress pathology report of the Italian PROSIT study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006019.PUB2

7 January 2021

Neoadjuvant hormonal therapy: the Canadian experience

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006019.PUB2

7 January 2021

Preliminary results of a prospective randomized study comparing radical prostatectomy versus radical prostatectomy associated with neoadjuvant hormonal combination therapy in T2-3 N0 M0 prostatic carcinoma. The European Study Group on Neoadjuvant Tr

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006019.PUB2

7 January 2021

CUOG randomized trial of neoadjuvant androgen ablation before radical prostatectomy: 36-month post-treatment PSA results. Canadian Urologic Oncology Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006019.PUB2

7 January 2021

Tumor cell proliferation in prostate cancer after 3 months of neoadjuvant LHRH analogue treatment is a prognostic marker of recurrence after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006019.PUB2

7 January 2021

Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radiation Therapy Oncology Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006019.PUB2

7 January 2021

Acute Toxicity of Conventional Radiation Therapy for High-Risk Prostate Cancer in EORTC Trial 22863

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006019.PUB2

7 January 2021

Effect of total androgen ablation on pathologic stage and resection limit status of prostate cancer. Initial results of the Italian PROSIT study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006019.PUB2

7 January 2021

Beneficial effect of combination hormonal therapy administered prior and following external beam radiation therapy in localized prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006019.PUB2

7 January 2021

Androgen suppression plus radiation versus radiation alone for patients with D1 (pN+) adenocarcinoma of the prostate (results based on a national prospective randomized trial, RTOG 85-31). Radiation Therapy Oncology Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006019.PUB2

7 January 2021

Prostate cancer patient subsets showing improved bNED control with adjuvant androgen deprivation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006019.PUB2

7 January 2021

Conventional external-beam radiation therapy alone or with androgen ablation for clinical stage III (T3, NX/N0, M0) adenocarcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006019.PUB2

7 January 2021

Early results of radical prostatectomy and adjuvant endocrine therapy for prostate cancer with or without preoperative androgen deprivation. The Prostate Cancer Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006019.PUB2

7 January 2021

Pathological staging and biochemical recurrence after neoadjuvant androgen deprivation therapy in combination with radical prostatectomy in clinically localized prostate cancer: results of a phase II study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006019.PUB2

7 January 2021

Neoadjuvant strategies for prostate cancer prior to radical prostatectomy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006019.PUB2

7 January 2021

Improved Survival in Patients with Locally Advanced Prostate Cancer Treated with Radiotherapy and Goserelin

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006019.PUB2

7 January 2021

Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006019.PUB2

7 January 2021

Neoadjuvant hormonal therapy before radical prostatectomy decreases the number of positive surgical margins in stage T2 prostate cancer: interim results of a prospective randomized trial. The Belgian Uro-Oncological Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006019.PUB2

7 January 2021

The efficacy and sequencing of a short course of androgen suppression on freedom from biochemical failure when administered with radiation therapy for T2-T3 prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006019.PUB2

7 January 2021

Treatment of advanced localised prostatic cancer by orchiectomy, radiotherapy, or combined treatment. A Medical Research Council Study. Urological Cancer Working Party--Subgroup on Prostatic Cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006019.PUB2

7 January 2021

4-Year follow-up results of a European prospective randomized study on neoadjuvant hormonal therapy prior to radical prostatectomy in T2-3N0M0 prostate cancer. European Study Group on Neoadjuvant Treatment of Prostate Cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006019.PUB2

7 January 2021

The risk of malignancy in the surgical margin at radical prostatectomy reduced almost three-fold in patients given neo-adjuvant hormone treatment

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006019.PUB2

7 January 2021

Effects of 3 Months' Neoadjuvant Hormonal Treatment with a GnRH Analogue (Triptorelin) prior to Radical Retropubic Prostatectomy on Prostate-Specific Antigen and Tumour Volume in Prostate Cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006019.PUB2

7 January 2021

A multicentre trial of combined neoadjuvant androgen blockade with Zoladex and flutamide prior to radical prostatectomy in prostate cancer. The European Study Group on Neoadjuvant Treatment

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006019.PUB2

7 January 2021

Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006019.PUB2

7 January 2021

Intermittent versus continuous total androgen blockade in the treatment of patients with advanced hormone-naive prostate cancer: results of a prospective randomized multicenter trial.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006019.PUB2

7 January 2021